

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Innovent

信達生物製藥

INNOVENT BIOLOGICS, INC.

(Incorporated in the Cayman Islands with Limited Liability)

(Stock Code: 1801)

DATE OF BOARD MEETING

The board (the “**Board**”) of directors (the “**Directors**”) of Innovent Biologics, Inc. (the “**Company**”) hereby announces that a meeting of the Board will be held on Wednesday, August 27, 2025 for the purpose of, among others, considering and approving the interim results of the Company and its subsidiaries for the six months ended June 30, 2025 and its publication and considering the recommendation of payment of a interim dividend (if any).

By order of the Board
Innovent Biologics, Inc.
Dr. De-Chao Michael Yu
Chairman and Executive Director

Hong Kong, China, August 4, 2025

As at the date of this announcement, the Board comprises Dr. De-Chao Michael Yu as Chairman and executive Director and Mr. Ronald Hao Xi Ede and Ms. Qian Zhang as executive Directors, and Dr. Charles Leland Cooney, Ms. Joyce I-Yin Hsu, Mr. Gary Zieziula, Dr. Shun Lu and Mr. Shuyun Chen as independent non-executive Directors.